Skip to main content
Year archive

Alligator Bioscience — 2023 filings

All 63 regulatory filings released by Alligator Bioscience (ATORX) in 2023, sourced directly from the official regulator.

63 Filings
2023 Period
2023 filings (63)
Filing Released Lang
Major Shareholding Notification 2023
Major Shareholding Notification
2023-11-15 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-11-07 English
Correction: Nomination Committee appointed in respect of AGM 2024 in Alligator Bioscience AB
AGM Information
2023-11-06 English
Rättelse: Valberedning utsedd inför årsstämma 2024 i Alligator Bioscience AB
AGM Information
2023-11-06 Swedish
Nomination Committee appointed in respect of AGM 2024 in Alligator Bioscience AB
Regulatory Filings
2023-11-06 English
Valberedning utsedd inför årsstämma 2024 i Alligator Bioscience AB
Regulatory Filings
2023-11-06 Swedish
Declaration of Voting Results & Voting Rights Announcements 2023
Declaration of Voting Results & Voting Rights Announcements
2023-11-03 English
Interim / Quarterly Report 2023
Interim / Quarterly Report 9M 2023
2023-10-26 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Q3 2023
2023-10-26 English
Ändring av antalet aktier och röster i Alligator Bioscience AB
Declaration of Voting Results & Voting Rights Announcements
2023-09-29 Swedish
Change in number of shares and votes in Alligator Bioscience AB
Declaration of Voting Results & Voting Rights Announcements
2023-09-29 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-08-21 English
Alligator Bioscience Receives European Medicine Agency Orphan Designation for Mitazalimab in Pancreatic Cancer
Regulatory Filings
2023-08-21 English
Alligator Bioscience erhåller särläkemedelsklassificering från den europeiska läkemedelsmyndigheten EMA för mitazalimab i bukspottkörtelcancer
Regulatory Filings
2023-08-21 Swedish
Declaration of Voting Results & Voting Rights Announcements 2023
Declaration of Voting Results & Voting Rights Announcements
2023-08-10 Swedish
Major Shareholding Notification 2023
Major Shareholding Notification
2023-08-08 Swedish
Declaration of Voting Results & Voting Rights Announcements 2023
Declaration of Voting Results & Voting Rights Announcements
2023-08-01 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-07-28 English
Interim / Quarterly Report 2023
Interim / Quarterly Report H1 2023
2023-07-13 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Q2 2023
2023-07-13 English
Director's Dealing 2023
Director's Dealing
2023-07-10 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-07-07 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-07-06 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-07-05 English
Declaration of Voting Results & Voting Rights Announcements 2023
Declaration of Voting Results & Voting Rights Announcements
2023-07-04 English
Director's Dealing 2023
Director's Dealing
2023-07-03 Swedish
Change in number of shares and votes in Alligator Bioscience AB
Declaration of Voting Results & Voting Rights Announcements
2023-06-30 English
Ändring av antalet aktier och röster i Alligator Bioscience AB
Declaration of Voting Results & Voting Rights Announcements
2023-06-30 Swedish
Alligator Bioscience Announces Positive Second Interim Efficacy Analysis from Mitazalimab OPTIMIZE-1 Phase 2 Study in 1st Line Pancreatic Cancer
Earnings Release FY 2023
2023-06-26 English
Alligator Bioscience tillkännager positiva effektdata från den andra interimsanalysen från fas 2-studien OPTIMIZE-1 med mitazalimab i bukspottkörtelcancer
Legal Proceedings Report
2023-06-26 Swedish
Major Shareholding Notification 2023
Major Shareholding Notification
2023-05-29 English
Kommuniké från årsstämma den 26 maj 2023 i Alligator Bioscience AB
AGM Information
2023-05-26 Swedish
Bulletin from the annual general meeting in Alligator Bioscience AB on 26 May 2023
AGM Information
2023-05-26 English
Alligators offentliggör tilläggsprospekt
Report Publication Announcement
2023-05-24 Swedish
Alligator publishes supplementary prospectus
Capital/Financing Update
2023-05-24 English
Alligator Bioscience erhåller särläkemedelsklassificering från FDA för mitazalimab i bukspottkörtelcancer
Regulatory Filings
2023-05-18 Swedish
Alligator Bioscience Receives FDA Orphan Drug Designation for Mitazalimab in Pancreatic Cancer
Regulatory Filings
2023-05-18 English
Alligator announces preliminary outcome of rights issue
Capital/Financing Update
2023-05-12 English
Alligator offentliggör preliminärt utfall i företrädesemission
Capital/Financing Update
2023-05-12 Swedish
Alligators offentliggör tilläggsprospekt
Capital/Financing Update
2023-05-12 Swedish
Alligator publishes supplementary prospectus
Report Publication Announcement
2023-05-12 English
Alligator Bioscience and Orion Corporation announce exercise of development option under their 2021 Immuno-oncology Research Collaboration and License Agreement
Regulatory Filings
2023-05-11 English
Alligator Bioscience och Orion Corporation meddelar att utvecklingsmöjlighet nyttjats inom bolagens immunonkologiska forskningssamarbete och licensavtal från 2021
Regulatory Filings
2023-05-11 Swedish
Alligator publishes supplementary prospectus
Report Publication Announcement
2023-05-09 English
Alligators offentliggör tilläggsprospekt
Capital/Financing Update
2023-05-09 Swedish
Alligator Bioscience publishes prospectus in connection with forthcoming rights issue
Capital/Financing Update
2023-04-26 English
Alligator Bioscience offentliggör prospekt med anledning av förestående företrädesemission
Capital/Financing Update
2023-04-26 Swedish
Notice of annual general meeting in Alligator Bioscience AB
Proxy Solicitation & Information Statement
2023-04-26 English
Kallelse till årsstämma i Alligator Bioscience AB
Proxy Solicitation & Information Statement
2023-04-26 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Q1 2023
2023-04-25 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Q1 2023
2023-04-25 English
Bulletin from the extraordinary general meeting in Alligator Bioscience AB
AGM Information
2023-04-24 English
Kommuniké från extra bolagsstämma i Alligator Bioscience AB
AGM Information
2023-04-24 Swedish
Annual Report (ESEF) 2022
Annual Report (ESEF) FY 2022
2023-03-24 Swedish
Annual Report (ESEF) 2022
Annual Report (ESEF) FY 2022
2023-03-24 Swedish
Alligator intends to carry out a 91 percent secured rights issue of units of approximately SEK 199 million
Share Issue/Capital Change
2023-03-22 English
Alligator avser att genomföra en till 91 procent säkerställd företrädesemission av units om cirka 199 MSEK
Capital/Financing Update
2023-03-22 Swedish
Earnings Release 2022
Earnings Release Q4 2022
2023-02-10 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Q4 2022
2023-02-10 English
Alligator Bioscience rapporterar positiva fas 2-data med över 50% ORR från studien OPTIMIZE-1, som utvärderar mitazalimab i bukspottskörtelcancer
Report Publication Announcement
2023-01-02 Swedish
Alligator Bioscience Announces Positive Interim Results from Mitazalimab OPTIMIZE-1 Phase 2 Trial in Pancreatic Cancer Exceeding 50% Objective Response Rate
Earnings Release FY 2023
2023-01-02 English
Alligator Bioscience och Orion Corporation meddelar att ett andra program inletts under det tidigare ingångna forskningssamarbetet och licensavtalet
Regulatory Filings
2023-01-02 Swedish
Alligator Bioscience and Orion Corporation announce the initiation of the second program of their Immuno-oncology Research Collaboration and License Agreement
Regulatory Filings
2023-01-02 English